352 related articles for article (PubMed ID: 25202102)
1. 90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment.
Mondello P; Pitini V; Arrigo C; Derenzini E; Mian M
Anticancer Res; 2014 Sep; 34(9):5121-5. PubMed ID: 25202102
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of post-remission therapy using (90)yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma.
Han EJ; Lee SE; Kim SH; Sohn HS; Jung SE; Park G; Choi BO; Lee SN; Yang SW; Han K; Cho SG
Ann Hematol; 2011 Sep; 90(9):1075-82. PubMed ID: 21336624
[TBL] [Abstract][Full Text] [Related]
3. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
[TBL] [Abstract][Full Text] [Related]
4. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.
Fruchart C; Tilly H; Morschhauser F; Ghesquières H; Bouteloup M; Fermé C; Van Den Neste E; Bordessoule D; Bouabdallah R; Delmer A; Casasnovas RO; Ysebaert L; Ciappuccini R; Briere J; Gisselbrecht C
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1905-11. PubMed ID: 25072780
[TBL] [Abstract][Full Text] [Related]
5. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Hertzberg M; Gandhi MK; Trotman J; Butcher B; Taper J; Johnston A; Gill D; Ho SJ; Cull G; Fay K; Chong G; Grigg A; Lewis ID; Milliken S; Renwick W; Hahn U; Filshie R; Kannourakis G; Watson AM; Warburton P; Wirth A; Seymour JF; Hofman MS; Hicks RJ;
Haematologica; 2017 Feb; 102(2):356-363. PubMed ID: 28143954
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.
Zinzani PL; Rossi G; Franceschetti S; Botto B; Di Rocco A; Cabras MG; Petti MC; Stefoni V; Broccoli A; Fanti S; Pellegrini C; Montini GC; Gandolfi L; Derenzini E; Argnani L; Fina M; Tucci A; Bottelli C; Pileri S; Baccarani M
Clin Cancer Res; 2010 Aug; 16(15):3998-4004. PubMed ID: 20542986
[TBL] [Abstract][Full Text] [Related]
7. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
8. Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results.
Stefoni V; Casadei B; Bottelli C; Gaidano G; Ciochetto C; Cabras MG; Ansuinelli M; Argnani L; Broccoli A; Gandolfi L; Pellegrini C; Zinzani PL
Blood Cancer J; 2016 May; 6(5):e425. PubMed ID: 27176801
[TBL] [Abstract][Full Text] [Related]
9. Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.
Provencio M; Cruz Mora MÁ; Gómez-Codina J; Quero Blanco C; Llanos M; García-Arroyo FR; de la Cruz L; Gumá Padró J; Delgado Pérez JR; Sánchez A; Alvarez Cabellos R; Rueda A;
Leuk Lymphoma; 2014 Jan; 55(1):51-5. PubMed ID: 23573825
[TBL] [Abstract][Full Text] [Related]
10. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
[TBL] [Abstract][Full Text] [Related]
11. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
12. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
[TBL] [Abstract][Full Text] [Related]
13. Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma.
Yang DH; Kim WS; Kim SJ; Kim JS; Kwak JY; Chung JS; Oh SY; Suh C; Lee JJ
Leuk Lymphoma; 2012 May; 53(5):807-11. PubMed ID: 22035417
[TBL] [Abstract][Full Text] [Related]
14. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
Jung SH; Lee JJ; Kim WS; Lee WS; Do YR; Oh SY; Kim MK; Mun YC; Shin HJ; Kwak JY; Kang HJ; Won JH; Kwon JH; Park E; Suh C; Yang DH
Eur J Haematol; 2015 Jun; 94(6):504-10. PubMed ID: 25288018
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy.
Moore S; Peggs K; Thomson K; Lowry L; Ljubic A; Goldstone AH; Linch DC; Ardeshna KM
Br J Haematol; 2012 Jan; 156(1):142-3. PubMed ID: 21848889
[No Abstract] [Full Text] [Related]
17. Rituximab-PECC induction followed by
Lugtenburg PJ; Zijlstra JM; Doorduijn JK; Böhmer LH; Hoogendoorn M; Berenschot HW; Beeker A; van der Burg-de Graauw NC; Schouten HC; Bilgin YM; Kersten MJ; Koene HR; Herbers AHE; de Jong D; Hijmering N; Lam KH; Chiţu D; Brouwer RE; van Imhoff GW;
Br J Haematol; 2019 Nov; 187(3):347-355. PubMed ID: 31290569
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
[TBL] [Abstract][Full Text] [Related]
19. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation.
Hung MH; Yu YB; Huang YC; Liu HT; Hong YC; Hsiao LT; Liu JH; Gau JP; Chiou TJ; Chen PM; Tzeng CH; Liu CY
Ann Hematol; 2012 Dec; 91(12):1907-15. PubMed ID: 22885989
[TBL] [Abstract][Full Text] [Related]
20. Autologous hematopoietic stem cell transplantation as first-line consolidation therapy can improve the prognosis of diffuse large B-cell lymphoma with high expression of MYC protein.
Hu K; Gao JJ; Li QH; Tian L; Wan W; Zhao W; Wang JJ; Fu L
Kaohsiung J Med Sci; 2019 Jul; 35(7):425-431. PubMed ID: 31050117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
